AMW signs License and Supply Agreement for Commercialization of its Goserelin and Leuprorelin implants in Israel

• AMW grants license to undisclosed partner for commercialization of its goserelin and leuprorelin implants in Israel
• Strengthening of availability of goserelin and leuprorelin for patients suffering from prostate and breast cancer, as well as other indications as per approved label
• Continued expansion of AMW’s products in MENA

Warngau, 19. Oktober 2021

AMW GmbH, a specialty pharmaceutical company focused on innovative drug delivery systems, today announced that it has entered into license and supply agreements (LSA) with an undisclosed partner for the commercialization of its goserelin and leuprorelin implants in the country of Israel.

AMW’s new partner is highly experienced in the registration and commercialization of pharmaceutical products and will help to bring improved medication to patients within Israel.

Under the terms of the agreements, the partner will distribute goserelin and leuprorelin in Israel. AMW will exclusively manufacture and supply goserelin and leuprorelin under pre-agreed terms and will receive royalty payments on its partner’s net sales.

To date, AMW has licensed goserelin and leuprorelin to global and local pharma leaders in more than 50 countries.

Konstantin Petropoulos, CEO of AMW GmbH commented: “We are pleased to continue our journey of enabling a broader reach of our products to patients diagnosed with prostate or breast cancer, among others. As a market leader for biodegradable slow-release drug delivery systems, we continue to make goserelin and leuprorelin available for patients across the globe.”

For more information, please contact:
or
Dr. Konstantin Petropoulos
+49 8024 470999-0

About AMW:
AMW GmbH is a specialty pharmaceutical company focused on innovative drug delivery systems. Products developed by AMW enable the administration of drugs via implants (subcutaneous) or patches (transdermal). The company was founded in 2008 and develops therapeutic solutions in oncology, neurology, dermatology, pain management, and ophthalmology. AMW currently has four products on the market (goserelin & leuprorelin implants, rivastigmin & buprenorphine patches).
AMW is based in Warngau, south of Munich.

About Goserelin:
Goserelin belongs to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of the sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormone-sensitive tumors such as prostate cancer or breast cancer with goserelin. In addition, goserelin is used to treat certain benign gynecological disorders. Goserelin is administered in form of a biodegradable implant which releases the active ingredient over a period of either one or three months.

About Leuprorelin:
Leuprorelin belongs to the class of GnRH agonists (analogues of gonadotropin releasing hormone) which interfere with the regulation of the sex hormone balance. As a consequence, testosterone levels are lowered in men and estradiol levels are lowered in women. This artificially induced lowering of hormone levels enables the symptomatic therapy of hormone-sensitive tumors such as prostate cancer or breast cancer with leuprorelin. In addition, leuprorelin is used to treat certain benign gynecological disorders. Leuprorelin is administered in form of a biodegradable implant which releases the active ingredient over a period of three months.